Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Find the perfect cards to make your season’s greetings go even further. Every pack purchased will help fund vital research and support for people living with type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > Resource hub > ATTD 2025: Nadia Swann’s round up
ATTD is where over 5,000 healthcare professionals, technology and pharmaceutical companies from all over the world get together to share what they know about the latest breakthroughs and developments. It’s always an exciting and uplifting place, so I thought I’d share some of the things I saw and heard there, particularly around new technologies.
On the tech side, I was keen to hear about progress toward fully closed loop (FCL) systems, which unlike hybrid closed loop (HCL) systems, handle both basal adjustments and meal bolusing, eliminating the need for carb counting.
While there are a few people who build their own fully closed loop, we are still some way off having many systems commercially available that will free us from carb calculations and meal boluses. There are some fully closed loop systems in trials and one commercially available, but it requires you to wear two sensors and two pumps, so wouldn’t be suitable for many people.
Dr. Sufyan Hussain, an endocrinologist and someone who has lived with type 1 for 30 years, discussed the need to develop a fully closed loop system that offers the same functionality as the ‘build it yourself’ models, but with greater simplicity. Personally, I cannot wait for this and am following the trial work closely!
Breakthrough T1D have been part of funding a study called FCL@Home, which tested fully closed loop for five days under supervision and for seven days monitored at home. Prof Hovorka, who developed CamAPS FX, a hybrid closed loop system said that he had not seen many trials yet where FCL performed better than HCL because for this we need faster insulins, but, for me, the quality of life which comes from no meal bolusing will be really significant.
In the exhibition hall, I came across a couple of other interesting tech developments. One is continuous ketone monitoring or CKM, which can be used as an early warning system to tell people when their ketones are high in order to reduce the risk of diabetic ketoacidosis. I think I would want to see that in one sensor with a CGM ultimately though, as wearing two sensors might not suit some people.
I was really interested in a stand from a company that makes an inhalable insulin that isn’t available in the UK yet. This product is designed to allow people with type 1 to inhale a mealtime dose of insulin rather than injecting a bolus. Anything that means fewer injections has got to be a good thing, I think.
A huge area of development is early detection of type 1, which involves screening for autoantibodies that give us warning that type 1 diabetes may be developing. This is important is because we now have something which might slow down the development of type 1 diabetes, a medication called teplizumab, which was also a hot topic at ATTD, as screening programmes progress.
There is currently a project called EDENT1F1 where 200,000 children across 13 countries are being screened for type 1 diabetes biomarkers. We already have early data showing that screening can reduce hospitalisation and DKA. This large-scale is adding strength to the data we have.
One of the highlights of the week for me was the session where researchers talked about their latest work on insulin producing beta cells and the immune system cells that attack them in type 1 diabetes.
There were so many attendees keen to learn about the latest research that people had to sit on the floor (me included) to hear it! It’s a complicated area and includes a range of ideas from trying to regenerate beta cells using medication, to looking at how we can use stem cells to make replacement beta cell islets.
My personal favourite, because it sounds so futuristic, was the talk given by Prof Hebrok. He explained how we may be able to use ‘suppressor cells’ to form a shield or protection around the islet to protect them from immune attack.
A challenge, of course, with most kinds of beta cell therapy currently is that you still need to take immunosuppressant drugs to prevent rejection by the body and prevent the attack from the immune system. There was much discussion about ways to reduce or prevent this in the future.
The great thing about the suppressor cells research is that immunosuppressant drugs may not be needed in order to stop transplanted islets being rejected. The suppressor cells may work to suppress the immune system response locally (e.g. just in one organ like the kidney or pancreas) rather than suppressing the immune system in the whole body. It’s early days for this research, but it looks promising!
What I really took away from this week is the number of times researchers and professors thanked Breakthrough T1D for their support and how they could not have carried out some of this amazing research without us.
So really, they were thanking you. It’s your support that makes this work possible. Your support is changing the world of living with type 1 diabetes. I saw with my own eyes this week how it really is making a difference in the incredibly complex world of type 1 diabetes research.
Youth Ambassador Eden sat down with Professor Shareen Forbes from the University of Edinburgh about her fascinating research exploring the role of antigens in improving islet transplant success rates, made possible through our global research programme. She tells us about the personal reasons driving her work and how her findings could help people with type 1 diabetes (T1D).
Breakthrough T1D has led an international expert group of leading type 1 diabetes researchers, clinicians and screening specialists to set out consensus guidance on screening the general population for early stage type 1 diabetes (T1D).
Renuka Dias, professor at the University of Birmingham and consultant at Birmingham Women’s and Children’s NHS Foundation Trust, discusses the early type 1 diabetes (T1D) clinic that she has set up in her city.
The Autumn 2026 issue features European jiu-jitsu champion Megan on why type 1 diabetes should never stand in your way.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
